Connection

Annamaria Colao to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Annamaria Colao has written about Antineoplastic Agents.
Annamaria Colao
Connection Strength
1.553
Antineoplastic Agents
  1. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. J Clin Endocrinol Metab. 2020 01 01; 105(1).
    View in: PubMed
    Score: 0.260
  2. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature. Endocr Relat Cancer. 2018 06; 25(6):R351-R364.
    View in: PubMed
    Score: 0.231
  3. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study. Endocrine. 2018 10; 62(1):46-56.
    View in: PubMed
    Score: 0.230
  4. Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. Metabolism. 2018 01; 78:141-154.
    View in: PubMed
    Score: 0.223
  5. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf. 2017 Oct; 16(10):1149-1161.
    View in: PubMed
    Score: 0.220
  6. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019 11; 66(2):417-424.
    View in: PubMed
    Score: 0.062
  7. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. Endocrine. 2018 12; 62(3):663-680.
    View in: PubMed
    Score: 0.059
  8. Nutrition and neuroendocrine tumors: An update of the literature. Rev Endocr Metab Disord. 2018 06; 19(2):159-167.
    View in: PubMed
    Score: 0.058
  9. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocr Relat Cancer. 2018 09; 25(9):R453-R466.
    View in: PubMed
    Score: 0.058
  10. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology. 2018 08; 155(2):479-489.e7.
    View in: PubMed
    Score: 0.058
  11. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. J Cancer Res Clin Oncol. 2017 Jul; 143(7):1209-1224.
    View in: PubMed
    Score: 0.054
  12. Targeted therapy with kinase inhibitors in aggressive endocrine tumors. Expert Opin Pharmacother. 2013 Jun; 14(9):1187-203.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.